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Background: High-dose bolus (HDB) tirofiban (25 μg/kg bolus followed by 0.15 μg/kg/min infusion) has been demonstrated to provide higher 
inhibition of platelet aggregation compared to the standard-dose tirofiban. However, the relative efficacy and safety of HDB tirofiban versus 
abciximab for primary percutaneous coronary intervention (PPCI) remains controversial. We therefore performed a meta-analysis of all currently 
available randomized controlled trials (RCT) to compare HDB tirofican versus abciximab in ST-segment elevation myocardial infarction (STEMI) 
patients scheduled for PPCI.
Methods: The published literature was scanned by formal searches of electronic databases (PubMed, EMBASE and the Cochrane Central Register 
of Controlled Trials) and conference proceedings up through August 2009. RCTs were eligible for inclusion if they compared HDB tirofiban versus 
abciximab as adjunctive therapy to PPCI for STEMI and had the data of efficacy and safety endpoints reported by the trial investigators.
Results: A total of five RCTs meeting the prespecified criteria were finally included, involving 1770 patients (889 in the HDB tirofiban group, 881 in 
the abciximab group). Rates of initial TIMI 3 flow before procedure (16.7% vs. 16.2%) as well as complete ST resolution after PPCI (73.2% vs. 73.4%) 
were not inferior in HDB tirofiban group compared with abciximab group (odds ratio [OR] 1.04, 95% confidence interval [CI] 0.80 to 1.35, P = 0.76; 
and OR 0.98, 95% CI 0.78 to 1.24, P = 0.86, respectively). And there was no significant difference in the risk of 30-day (1.6% vs. 1.9%, OR 0.82, 
95% CI 0.41 to 1.66, P = 0.58) or 8-month mortality (3.9% vs. 5.0%, OR 0.78, 95% CI 0.41 to 1.46, P = 0.43) between the HDB tirofiban group and 
the abciximab group. With regard to the safety endpoints, neither the major (1.9% vs. 1.6%) nor the minor bleeding complications (3.3% vs. 4.7%) in 
the HDB tirofiban group differed significantly from those in the abciximab group (OR 1.20, 95% CI 0.60 to 2.43, P = 0.61; and OR 0.70, 95% CI 0.43 
to 1.13, P = 0.14, respectively).
Conclusions: This meta-analysis shows that HDB tirofiban is as effective as abciximab in the setting of PPCI for STEMI without an increase in 
bleeding risk.
